| Overview |
| bs-70538r-100ul |
| Leupaxin (N-terminal region) Antibody |
| WB |
| The antibody detects a 45 kDa* proteins corresponding to the apparent molecular mass of leupaxin on SDS-PAGE immunoblots of human A431 epithelial cells, human PC3 prostate cells, and rat A7r5 smooth muscle cells. This peptide sequence is highly conserved in rat and mouse leupaxin, and has low homology to other paxillin family proteins. |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Leupaxin (N-terminal) synthetic peptide (coupled to KLH) corresponding to amino acid residues in the N-terminal region of human leupaxin. |
| Polyclonal |
| IgG |
| Antigen Affinity purification |
| PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| O60711 |
| Paxillin |
| The paxillin family of LIM domain-containing proteins includes paxillin, Hic-5, and leupaxin. Similar to other family members, leupaxin is composed of multiple functional modules, including leucine and aspartate motifs and LIM domains. These domains suggest that leupaxin is a molecular adaptor that may be important for integrin-mediated cell signaling. Leupaxin was identified in leukocytes, and has been shown to be expressed in non-hematopoietic lineage cells, including vascular smooth muscle cells and certain cancer cells. In prostate cancer cells, leupaxin expression intensity is directly linked to cancer progression. Leupaxin localizes to the podosomal signaling complex in murine osteoclasts where it may be important for rearrangement of cytoskeletal components. The function of leupaxin in regulating the cytoskeleton may involve protein-protein interactions between leupaxin and focal adhesion proteins, such as Pyk2, FAK, Src, Lyn, and PTP-PEST. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz